Skip to main content
. 2017 Nov 14;19:120. doi: 10.1186/s13058-017-0911-9

Table 2.

Frequency distribution of PAM50 intrinsic subtypes and risk of recurrence score

All patients Node-negative patientsa Node-positive patientsa
No. of patients % No. of patients % No. of patients %
All patients 653 100 419 64.2 218 33.4
 PAM50 intrinsic subtype
  Luminal A 341 52.2 240 57.3 95 43.6
  Luminal B 173 26.5 103 24.6 65 29.8
  HER2enriched 69 10.6 30 7.2 38 17.4
  Basal-like 70 10.7 46 11.0 20 9.2
 ROR score, median 51 46 56
HR+/HER2− patients 476 100 318 66.8 149 31.3
 ROR risk score classification
  Low risk 180 37.8 145 45.6 33 22.1
  Intermediate risk 108 22.7 104 32.7
  High risk 188 39.5 69 21.7 116 77.9
 ROR score, median 46 42 50

Abbreviations: HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, ROR Risk of recurrence

aNine patients were classified as pNX